ARTICLE | Product Development
MedImmune scrambles back
January 22, 1996 8:00 AM UTC
MedImmune Inc.'s fortunes came full circle last week when the company received FDA approval to market RespiGam, its intravenous immune globulin against respiratory syncytial virus (RSV) disease, and announced a marketing partnership with Wyeth-Ayerst Laboratories.
The approval marks the end of a lengthy road for RespiGam and the company, which was lauded by several analysts as a "can't miss" proposition in 1993. With its CytoGam cytomegalovirus product on the market; RespiGam about to be approved; a deal with American Cyanamid to co-market the anti-infective Zosyn and develop additional products; and a deal in hand to acquire Melville Biologics from the New York Blood Center for $40 million, the momentum seemed unstoppable...